ContributorsPublishersAdvertisers

Positive Response Rates Observed With Mirvetuximab Soravtansine for Platinum-Resistant Ovarian Cancer

cancernetwork.com
 2021-11-30

Cover picture for the articleEncouraging responses and safety data were observed in the phase 3 SORAYA trial, which analyzed mirvetuximab soravtansine monotherapy for patients with folate receptor α–high platinum-resistant ovarian cancer who previously received bevacizumab. Positive top-line data were seen from the phase 3 SORAYA trial (NCT04296890), investigating both the safety and efficacy...

www.cancernetwork.com

Comments / 0

Comments / 0